{"success":true,"data":{"pressRelease":{"id":"2583","rtpr_id":"nGNX7jYYtz","ticker":"PACS","exchange":"NYSE","all_tickers":["PACS"],"title":"PACS SHAREHOLDER ALERT: Kaskela Law Firm Announces Investigation of PACS Group, Inc.(PACS) and Encourages Long-Term PACS Investors with Losses to Contact the Firm","author":"Globe Newswire","published_at":"2026-04-21T12:00:01.858Z","article_body":"PHILADELPHIA, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Kaskela Law\n(https://www.globenewswire.com/Tracker?data=l2uI5mqlKGDy3HZQgS891jnmltFAA1xR1GRsaIV7Jml3prHp7RST_2zOe90Bdsr5sQbM1L7WO25taDmKdx2n7A==)\nis investigating potential breach of fiduciary duty claims concerning PACS\nGroup, Inc. (NYSE: PACS) (“PACS”) on behalf of the company’s long-term\nshareholders. \n\nClick here for additional information about your shareholder legal rights:\nhttps://kaskelalaw.com/case/pacs-group/ \n\nRecently a federal securities fraud complaint was filed against PACS on behalf\nof certain investors who purchased shares of the company’s stock between\nApril 11, 2024 and November 5, 2024 (the “Wrongdoing\nPeriod”).  According to the complaint, during the Wrongdoing Period, PACS\nand several of the company’s officers made a series of materially false and\nmisleading statements and omissions to investors regarding PACS’ rapid\ngrowth and profitability, primarily driven by the company’s manipulation of\nbilling practices that exploited taxpayer-funded programs. \n\nAs further detailed in the complaint, on November 4, 2024, Hindenburg Research\n(“Hindenburg”) published a report concerning PACS and detailing several\nallegations against the company, including evidence of PACS’ misuse of COVID\nwaivers to inflate Medicare reimbursements as well as other unsustainable\nrevenue practices which misrepresented the company’s financial health to\ninvestors.”  Following this news, shares of the company’s stock fell\n$11.93 per share, or over 27% in value, to close at $31.01 per share on\nNovember 4, 2024. \n\nThen, on November 6, 2024, PACS announced that it would delay the release of\nits third-quarter 2024 financial results, as the company’s Audit\nCommittee was conducting an investigation into recent third-party\nallegations concerning its reimbursement and referral practices.  Following\nthis disclosure, shares of the company’s stock fell an additional $11.45\nper share, or over 38% in value, to close at $18.09 per share on November 6,\n2024. \n\nIn light of the foregoing, Kaskela Law is investigating\nwhether PACS’ officers and directors violated the securities laws or\nbreached their fiduciary duties in connection with the above alleged\nmisconduct. \n\nCurrent PACS shareholders who have continuously held PACS shares since at\nleast April 11, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus\nKaskela, Esq. or Adrienne Bell, Esq.) to receive additional information about\nthis investigation and their legal rights and options at (484) 229 - 0750, via\nemail at abell@kaskelalaw.com, or by clicking on the following link (or if\nnecessary, by copying and pasting the link into your browser):\n\nhttps://kaskelalaw.com/case/pacs-group/ \n\nABOUT KASKELA LAW:    \n\nKaskela Law exclusively represents investors in securities fraud,\ncorporate governance, and merger & acquisition litigation on a contingent\nbasis. For additional information about the firm, including our recent\nmonetary recoveries for investors, please visit our website\n(www.kaskelalaw.com) or contact us today at (888) 715 – 1740.    \n\nKASKELA LAW LLC     \nD. Seamus Kaskela, Esquire    \nAdrienne Bell, Esquire    \n18 Campus Boulevard, Suite 100     \nNewtown Square, PA 19073     \n(484) 229 – 0750      \nwww.kaskelalaw.com \n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7jYYtz","title":"PACS SHAREHOLDER ALERT: Kaskela Law Firm Announces Investigation of PACS Group, Inc.(PACS) and Encourages Long-Term PACS Investors with Losses to Contact the Firm","author":"Globe Newswire","ticker":"PACS","created":"2026-04-21T12:00:01.858Z","tickers":["PACS"],"exchange":"NYSE","article_body":"PHILADELPHIA, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Kaskela Law\n(https://www.globenewswire.com/Tracker?data=l2uI5mqlKGDy3HZQgS891jnmltFAA1xR1GRsaIV7Jml3prHp7RST_2zOe90Bdsr5sQbM1L7WO25taDmKdx2n7A==)\nis investigating potential breach of fiduciary duty claims concerning PACS\nGroup, Inc. (NYSE: PACS) (“PACS”) on behalf of the company’s long-term\nshareholders. \n\nClick here for additional information about your shareholder legal rights:\nhttps://kaskelalaw.com/case/pacs-group/ \n\nRecently a federal securities fraud complaint was filed against PACS on behalf\nof certain investors who purchased shares of the company’s stock between\nApril 11, 2024 and November 5, 2024 (the “Wrongdoing\nPeriod”).  According to the complaint, during the Wrongdoing Period, PACS\nand several of the company’s officers made a series of materially false and\nmisleading statements and omissions to investors regarding PACS’ rapid\ngrowth and profitability, primarily driven by the company’s manipulation of\nbilling practices that exploited taxpayer-funded programs. \n\nAs further detailed in the complaint, on November 4, 2024, Hindenburg Research\n(“Hindenburg”) published a report concerning PACS and detailing several\nallegations against the company, including evidence of PACS’ misuse of COVID\nwaivers to inflate Medicare reimbursements as well as other unsustainable\nrevenue practices which misrepresented the company’s financial health to\ninvestors.”  Following this news, shares of the company’s stock fell\n$11.93 per share, or over 27% in value, to close at $31.01 per share on\nNovember 4, 2024. \n\nThen, on November 6, 2024, PACS announced that it would delay the release of\nits third-quarter 2024 financial results, as the company’s Audit\nCommittee was conducting an investigation into recent third-party\nallegations concerning its reimbursement and referral practices.  Following\nthis disclosure, shares of the company’s stock fell an additional $11.45\nper share, or over 38% in value, to close at $18.09 per share on November 6,\n2024. \n\nIn light of the foregoing, Kaskela Law is investigating\nwhether PACS’ officers and directors violated the securities laws or\nbreached their fiduciary duties in connection with the above alleged\nmisconduct. \n\nCurrent PACS shareholders who have continuously held PACS shares since at\nleast April 11, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus\nKaskela, Esq. or Adrienne Bell, Esq.) to receive additional information about\nthis investigation and their legal rights and options at (484) 229 - 0750, via\nemail at abell@kaskelalaw.com, or by clicking on the following link (or if\nnecessary, by copying and pasting the link into your browser):\n\nhttps://kaskelalaw.com/case/pacs-group/ \n\nABOUT KASKELA LAW:    \n\nKaskela Law exclusively represents investors in securities fraud,\ncorporate governance, and merger & acquisition litigation on a contingent\nbasis. For additional information about the firm, including our recent\nmonetary recoveries for investors, please visit our website\n(www.kaskelalaw.com) or contact us today at (888) 715 – 1740.    \n\nKASKELA LAW LLC     \nD. Seamus Kaskela, Esquire    \nAdrienne Bell, Esquire    \n18 Campus Boulevard, Suite 100     \nNewtown Square, PA 19073     \n(484) 229 – 0750      \nwww.kaskelalaw.com \n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-21T12:00:02.178398873Z","server_sent_at_ms":1776772802178},"received_at":"2026-04-21T12:00:02.233Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}